Verastem Oncology announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 and Russell Microcap Indexes, effective at the open of U.S. equity markets today, Monday, July 1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem Updates Corporate Presentation with Latest Insights
- Verastem partner GenFleet says China’s NMPA approved clinical trial application
- Verastem price target lowered to $20 from $34 at Alliance Global Partners
- Verastem price target lowered to $16 from $32 at RBC Capital
- Verastem sinks after 27% response rate in ovarian cancer study